Molecular Docking and Pharmacological In-silico evaluation of Nitrogen and oxygen Heterocyclic Compounds as promising anticancer agents with an aim of drug repurposing
Abstract
A
Cancer is one of the leading causes of death among deadly diseases that occur in humans. Due to its ability to spread and the uncontrolled cell growth, it affects various organs and tissues. The present study evaluates the interactions between two receptors, 6JOR (FLT3 in complex with Gilteritinib) and HER-2 (Human epidermal growth factor receptor 2), and five existing drugs, with different biological actions and Safety Profiles. The aim is to repurpose established drugs. Molecular dynamics (MD) simulation of the ligand with the target 6JOR showed the most likely binding for Albendazole, with an IDDT value of 0.6598. The Binding affinity prediction maximum for Aripiprazole (-7.24425). Gilteritinib gave IDDT value -6.228. GROMACS was used for dynamic binding and docking using the new wrap mime platform. Pharmacokinetic evaluation based on the rule of five and Prediction of Pharmacology by PASS online. This research highlights the significance of drug repurposing and eliminates the need for drugs with an established safety profile. The study of existing drugs with established safety profiles and in silico pharmacological activity prediction using PASS online leveraged insights into biological activity. Further clinical testing should be conducted to assess anticancer activity in Humans.
Keywords: Docking, Dynamics, Cancer, Heterocyclic, Nitrogen, Oxygen
Keywords:
Docking, Dynamics, Cancer, Heterocyclic, Nitrogen, OxygenDOI
https://doi.org/10.22270/jddt.v16i1.7493References
1. Weinberg, Robert A. "How cancer arises." Scientific American 1996;275(3):62-70. https://doi.org/10.1038/scientificamerican0996-62 PMid:8701295
2. Gerl, Robert, and David L. Vaux. "Apoptosis in the development and treatment of cancer." Carcinogenesis 2005;26(2):263-270. https://doi.org/10.1093/carcin/bgh283 PMid:15375012
3. Abbas, Zaigham, and Sakina Rehman. "An overview of cancer treatment modalities." Neoplasm 2018;1:139-157. https://doi.org/10.5772/intechopen.76558
4. Figueroa-Magalhães, Maria Cristina, et al. "Treatment of HER2-positive breast cancer." The Breast 2014;23(2):128-136. https://doi.org/10.1016/j.breast.2013.11.011 PMid:24360619 PMCid:PMC4466908
5. Marusyk, Andriy, and Kornelia Polyak. "Tumor heterogeneity: causes and consequences." Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2010;1805(1):105-117. https://doi.org/10.1016/j.bbcan.2009.11.002 PMid:19931353 PMCid:PMC2814927
6. Frączek, Natalia, et al. "An outline of main factors of drug resistance influencing cancer therapy." Journal of Chemotherapy 2016;28(6):457-464. https://doi.org/10.1080/1120009X.2016.1218158 PMid:27545330
7. Monje, Michelle, and Jörg Dietrich. "Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis." Behavioural brain research 2012;227(2):376-379. https://doi.org/10.1016/j.bbr.2011.05.012 PMid:21621557 PMCid:PMC3221863
8. Richardson, Jean L., Gary Marks, and Alexandra Levine. "The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy." Journal of Clinical Oncology 1988;6(11):1746-1752. https://doi.org/10.1200/JCO.1988.6.11.1746 PMid:3183704
9. Chauhan, Prashant, et al. "Unveiling the anticancer potential of phytocompounds: pioneering future cancer therapies." Current Topics in Medicinal Chemistry 2025;25(20):2417-2439. https://doi.org/10.2174/0115680266354680250121154720 PMid:39950280
10. Kumar, Adarsh, et al. "Nitrogen-containing heterocycles as anticancer agents: a medicinal chemistry perspective." Pharmaceuticals 2023;16(2):299. https://doi.org/10.3390/ph16020299 PMid:37259442 PMCid:PMC9965678
11. Abbas, Sumayah Saadi, et al. "Anticancer activities of some heterocyclic compounds containing an oxygen atom: a review." Al-Rafidain Journal of Medical Sciences, 2023;4:60-67. https://doi.org/10.54133/ajms.v4i.109
12. Cha, Y., et al. "Drug repurposing from the perspective of pharmaceutical companies." British journal of pharmacology 2018;175(2):168-180. https://doi.org/10.1111/bph.13798 PMid:28369768 PMCid:PMC5758385
13. Park, Kyungsoo. "A review of computational drug repurposing." Translational and clinical pharmacology 2019;27(2):59. https://doi.org/10.12793/tcp.2019.27.2.59 PMid:32055582 PMCid:PMC6989243
14. Khan, Ayad Kareem, Mohammed Dheyaa Hamdi, and Atheer Awad Mehde. "Drug Design, In Silico-Profiling of New Pyrrole Derivatives: Promising Anticancer Agents Against Acute Myeloid Leukemia." Al Mustansiriyah Journal of Pharmaceutical Sciences 2024;24(3):252-263. https://doi.org/10.32947/ajps.v24i3.1063
15. Satyanarayanajois, Seetharama, et al. "Design, synthesis, and docking studies of peptidomimetics based on HER2-Herceptin binding site with potential antiproliferative activity against breast cancer cell lines." Chemical biology & drug design 2009;74(3):246-257. https://doi.org/10.1111/j.1747-0285.2009.00855.x PMid:19703026 PMCid:PMC2866155
16. Jang, Yeonwoo, et al. "AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine/paclitaxel in cancer therapy." 2025. https://doi.org/10.21203/rs.3.rs-7307122/v1
17. Pandi, Sangavi, et al. "Decoding the anticancer and biofilm-inhibiting efficacy of Adansonia digitata using experimental, AI-powered, and molecular modeling approaches." Frontiers in Molecular Biosciences 2025;12:1666360. https://doi.org/10.3389/fmolb.2025.1666360 PMid:41234539 PMCid:PMC12605543
18. Filimonov, D. A., et al. "Prediction of the biological activity spectra of organic compounds using the PASS online web resource." Chemistry of Heterocyclic Compounds 2014;50(3):444-457. https://doi.org/10.1007/s10593-014-1496-1
19. Wei, L. et al. "DynamicBind: predicting ligand-specific protein-ligand complex structure with a deep equivariant generative model", https://nature.com, 05 February 2024, https://www.nature.com/articles/s41467-024-45461-2.
20. McNutt, A. T., Adduri, A. K., Ellington, C. N., Dayao, M. T., Xing, E. P., Mohimani, H., & Koes, D. R. Scaling Structure Aware Virtual Screening to Billions of Molecules with SPRINT. arXiv preprint arXiv:2411.15418. 2025
21. Abraham, J. M. et al., GROMACS: High-performance molecular simulations through multi-level parallelism from laptops to supercomputers, 2015, https://doi.org/10.1016/j.softx.2015.06.001
Published
Abstract Display: 27 
PDF Downloads: 23 PDF Downloads: 4 How to Cite
Issue
Section
Copyright (c) 2026 Thomas Kurian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.